雷贝拉唑联合莫沙必利治疗反流性食管炎疗效观察(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 观察雷贝拉唑联合莫沙必利治疗反流性食管炎的临床疗效。 方法 将2007～2010年来本院就诊的92例反流性食管炎患者采用随机方法分成两组，每组46例，治疗组应用雷贝拉唑和莫沙必利，对照组用法莫替丁和莫沙必利，观察治疗前后两组患者的临床症状改善和内镜变化。 结果 治疗6周，治疗组患者临床疗效显效率为78.3%、总有效率为93.5%，均显著高于对照组的39.1%和73.9%，两组临床疗效比较，差异有统计学意义(P < 0.05)；内镜复查治疗组食管炎愈合总有效率为91.3%，明显高于对照组的73.9%，两组间比较，差异有统计学意义(P < 0.05)。 结论 雷贝拉唑联合莫沙必利治疗反流性食管炎服用方便，不良反应少，疗效显著，值得临床推广应用。
[关键词] 雷贝拉唑；莫沙必利；反流性食管炎；疗效观察
[中图分类号] R571 [文献标识码] A [文章编号] 1674-4721(2012)03(a)-0076-02
Observation on therapeutic effect of rebeprazole combined with mosapride curing reflux esophagitis
CHEN Xiongjie1 RONG Jianwei2
1.Department of Internal Medicine, Beidou Hospital of Taishan City in Guangdong Province, Taishan 529238, China; 2.Gastroscopy Room of Taishan TCM Hospital in Guangdong Province, Taishan 529200, China
[Abstract] Objective To observe the efficacy of reflux esophagitis (RE) treated by rebeprazole combined with mosapride. Methods Ninty two cases of RE treated in our hospital between 2007 to 2010 was randomized to two groups, 46 cases in each group. The treatment group were treated with rebeprazole and mosapride. The control group were treated by famotidine and mosapride. The change in symptom and endoscope before and after treatment were observed. Results After treated for 6 weeks, the obviously effective rate and response rate of clinical in treatment group were 78.3% and 93.5%. They were significantly increased in the date of the control group (39.1%, 73.9%) (P < 0.05). Esophageal mucosa erosion was coalesce, the percentage was 91.3% and 73.9%, there was significant difference with the two groups (P < 0.05). Conclusion Rebeprazole combined with mosapride to treat RE has notable curative effect, easy administration, and less adverse reaction. It is worthy to be popularized in clinic.
[Key words] Rebeprazole; Mosapride; Reflux esophagitis; Therapeutic effect observation
反流性食管炎(reflux esophagitis，RE)是消化系统常见病，是由多种因素导致的上消化道运动障碍，由于胃或十二指肠内容物反流进入食管导致的食管黏膜在胃酸和胃蛋白酶作用下受到损伤。RE属于胃食管反流病(GERD)的一种。流行病学调查显示人群中7%～15%有胃食管反流症状[1]，临床上根据患者病情轻重，可采用质子泵抑制剂(PPI)或H2受体阻滞剂(H2RA)及联合应用促动力药进行治疗。本科应用新型PPI制剂雷贝拉唑联合新型强效促胃动力药物莫沙必利治疗反流性食管炎 ......
您现在查看是摘要介绍页，详见PDF附件(1397kb)。